Previous Close | 0.2920 |
Open | 0.2820 |
Bid | 0.2780 x N/A |
Ask | 0.3120 x N/A |
Day's Range | 0.2820 - 0.2820 |
52 Week Range | 0.1110 - 1.6300 |
Volume | |
Avg. Volume | 81 |
Market Cap | 42.237M |
Beta (5Y Monthly) | 1.98 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4200 |
Earnings Date | May 15, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
LONDON and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its third quarter fiscal year 2024 financial results on Wednesday, May 15, 2024 before U.S. market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST) on the day. Conference
LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per NASDAQ ADS ($0.375 per common stock share) (£0.0025 each) (the “Ordinary Shares”) (the “Fundraise”) to DB Capital Partners Healthcare, L.P. (the “Purchaser”), a specialty healthcare institutional investor focused on innovative medical technology that fundamentally changes critical global diseas
Guidelines highlight the importance of risk prediction and personalized treatment to reduce riskLONDON and SALT LAKE CITY, March 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (Renalytix) announces that the KidneyIntelX In-Vitro Diagnostic test has been included in the final KDIGO (Kidney Disease Improving Global Outcomes) 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD), published on March 13, 2024. In the release of the n